Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity

Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity

Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast can...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in molecular medicine 2020-04, Vol.26 (4), p.354-356
Hauptverfasser: Boese, Austin C., Kang, Sumin
Format: Artikel
Sprache:eng
Schlagworte:
BMAL1
insulin treatment
metabolism
obesity
triple-negative breast cancer
tumor suppressor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 356
container_issue 4
container_start_page 354
container_title Trends in molecular medicine
container_volume 26
creator Boese, Austin C.
Kang, Sumin
description Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.
doi_str_mv 10.1016/j.molmed.2020.01.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2388827283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471491420300423</els_id><sourcerecordid>2388827283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-42f96cac5c8af32cf71eb8ffa4886e3e9ee9dcca02abad68c0d7f34597c21ade3</originalsourceid><addsrcrecordid>eNp9kNFLwzAQxoMobk7_A5E--tKZpFmTvghuqBMG82GCbyFNLyOjbWbSCvvvzajzUfjgPrjv7rgfQrcETwkm-cNu2ri6gWpKMcVTTKLYGRoTxknKiuLz_M8TNkJXIewwJjPOxSUaZZRyXtBijOabvnE-efdu6yEE69rEmWTuQYUuWahWg0-q3tt2mywPe4gm9LVtobE6WZcQbHe4RhdG1QFufusEfbw8bxbLdLV-fVs8rVKd5bRLGTVFrpWeaaFMRrXhBEphjGJC5JBBAVBUWitMVamqXGhccZOxWcE1JaqCbILuh7177756CJ1sbNBQ16oF1wdJMyEE5VRkMcqGqPYuBA9G7r1tlD9IguWRntzJgZ480pOYRLE4dvd7oS-PvdPQCVcMPA4BiH9-W_AyaAsRUmU96E5Wzv5_4QcBi4Q1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2388827283</pqid></control><display><type>article</type><title>Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Boese, Austin C. ; Kang, Sumin</creator><creatorcontrib>Boese, Austin C. ; Kang, Sumin</creatorcontrib><description>Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.</description><identifier>ISSN: 1471-4914</identifier><identifier>EISSN: 1471-499X</identifier><identifier>DOI: 10.1016/j.molmed.2020.01.014</identifier><identifier>PMID: 32277929</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>BMAL1 ; insulin treatment ; metabolism ; obesity ; triple-negative breast cancer ; tumor suppressor</subject><ispartof>Trends in molecular medicine, 2020-04, Vol.26 (4), p.354-356</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-42f96cac5c8af32cf71eb8ffa4886e3e9ee9dcca02abad68c0d7f34597c21ade3</citedby><cites>FETCH-LOGICAL-c362t-42f96cac5c8af32cf71eb8ffa4886e3e9ee9dcca02abad68c0d7f34597c21ade3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.molmed.2020.01.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27913,27914,45984</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32277929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boese, Austin C.</creatorcontrib><creatorcontrib>Kang, Sumin</creatorcontrib><title>Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity</title><title>Trends in molecular medicine</title><addtitle>Trends Mol Med</addtitle><description>Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.</description><subject>BMAL1</subject><subject>insulin treatment</subject><subject>metabolism</subject><subject>obesity</subject><subject>triple-negative breast cancer</subject><subject>tumor suppressor</subject><issn>1471-4914</issn><issn>1471-499X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kNFLwzAQxoMobk7_A5E--tKZpFmTvghuqBMG82GCbyFNLyOjbWbSCvvvzajzUfjgPrjv7rgfQrcETwkm-cNu2ri6gWpKMcVTTKLYGRoTxknKiuLz_M8TNkJXIewwJjPOxSUaZZRyXtBijOabvnE-efdu6yEE69rEmWTuQYUuWahWg0-q3tt2mywPe4gm9LVtobE6WZcQbHe4RhdG1QFufusEfbw8bxbLdLV-fVs8rVKd5bRLGTVFrpWeaaFMRrXhBEphjGJC5JBBAVBUWitMVamqXGhccZOxWcE1JaqCbILuh7177756CJ1sbNBQ16oF1wdJMyEE5VRkMcqGqPYuBA9G7r1tlD9IguWRntzJgZ480pOYRLE4dvd7oS-PvdPQCVcMPA4BiH9-W_AyaAsRUmU96E5Wzv5_4QcBi4Q1</recordid><startdate>202004</startdate><enddate>202004</enddate><creator>Boese, Austin C.</creator><creator>Kang, Sumin</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202004</creationdate><title>Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity</title><author>Boese, Austin C. ; Kang, Sumin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-42f96cac5c8af32cf71eb8ffa4886e3e9ee9dcca02abad68c0d7f34597c21ade3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>BMAL1</topic><topic>insulin treatment</topic><topic>metabolism</topic><topic>obesity</topic><topic>triple-negative breast cancer</topic><topic>tumor suppressor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boese, Austin C.</creatorcontrib><creatorcontrib>Kang, Sumin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boese, Austin C.</au><au>Kang, Sumin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity</atitle><jtitle>Trends in molecular medicine</jtitle><addtitle>Trends Mol Med</addtitle><date>2020-04</date><risdate>2020</risdate><volume>26</volume><issue>4</issue><spage>354</spage><epage>356</epage><pages>354-356</pages><issn>1471-4914</issn><eissn>1471-499X</eissn><abstract>Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32277929</pmid><doi>10.1016/j.molmed.2020.01.014</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1471-4914
ispartof Trends in molecular medicine, 2020-04, Vol.26 (4), p.354-356
issn 1471-4914
1471-499X
language eng
recordid cdi_proquest_miscellaneous_2388827283
source Elsevier ScienceDirect Journals Complete - AutoHoldings
subjects BMAL1
insulin treatment
metabolism
obesity
triple-negative breast cancer
tumor suppressor
title Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A27%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20Progression%20of%20Breast%20Cancer%20during%20Hyperinsulinemic%20Obesity&rft.jtitle=Trends%20in%20molecular%20medicine&rft.au=Boese,%20Austin%20C.&rft.date=2020-04&rft.volume=26&rft.issue=4&rft.spage=354&rft.epage=356&rft.pages=354-356&rft.issn=1471-4914&rft.eissn=1471-499X&rft_id=info:doi/10.1016/j.molmed.2020.01.014&rft_dat=%3Cproquest_cross%3E2388827283%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2388827283&rft_id=info:pmid/32277929&rft_els_id=S1471491420300423&rfr_iscdi=true